Genomic Medicine

Genomic medicine promises to radically alter healthcare. By understanding the predictive power of patients' genomes and the products of those genomes, it should be possible to identify individuals at risk of disease and to create smarter, more effective treatments for those who are already ill.

The IGSP's research in genomic medicine is dedicated to making that happen. The strategy is to bring together programs, initiatives and experts working in various areas of medicine – from cardiovascular and infectious disease to cancer and primary care – all dedicated to translating genomic information into practical tools designed to inform clinical decision making and medical practice. It is our overarching aim to open up a pipeline of progress, allowing genomic advances to flow from discovery to translation to implementation.

As a foundational element, the IGSP has created a multi-disciplinary Clinical Genomics Studies Unit (CGSU) to design and execute genome-inspired clinical trials. We also rely on The Duke IGSP Biospecimen Repository, a standardized, regulatory compliant and privacy protected repository for fluid and tissue specimens and a newly designated Point of Care Molecular Diagnostics Development Laboratory that is a joint effort of the IGSP and the Pratt School of Engineering.